Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

Marieke Biegstraaten(Amsterdam UMC Location University of Amsterdam), Carla E. M. Hollak(Centre For Development Studies), Frank Weidemann(Katharinenhospital), Patrick Deegan(Addenbrooke's Hospital), Gabor E. Linthorst(Geneeskundige en Gezondheidsdienst), Claudia Sommer(Universitätsklinikum Würzburg), Ilkka Kantola(Turku University Hospital), Derralynn Hughes(Royal Free London NHS Foundation Trust), João Paulo Oliveira(Universidade do Porto), Wim Terryn(Ghent University Hospital), Atul Mehta(University College London), Einar Svarstad(Haukeland University Hospital), Uma Ramaswami(The Royal Free Hospital), Gere Sunder–Plassmann(University of Vienna), Annelies Sweeb(University of Twente), Frits A. Wijburg(Emma Kinderziekenhuis), Tarekegn Geberhiwot(Selly Oak Hospital), Frédéric Barbey(University Hospital of Lausanne), Anna Tylki‐Szymańska(Children's Memorial Health Institute), Camilla Tøndel(Haukeland University Hospital), Nesrin Karabul(German Center for Pediatric and Adolescent Rheumatology), Bojan Vujkovac(Šolski center Slovenj Gradec), Dominique P. Germain(Assistance Publique – Hôpitaux de Paris), Peter Woolfson(Salford Royal NHS Foundation Trust), Christian J. Hendriksz(Birmingham Children's Hospital), Rossella Parini(MRC Epidemiology Unit), Reynir Arngrı́msson(University of Iceland), Ulla Feldt‐Rasmussen(Copenhagen University Hospital), Andreas L. Serra(Klinik Hirslanden), Erica van de Mheen(Vector Fabrics (Netherlands)), Franco Cecchi(Azienda Ospedaliero-Universitaria Careggi), Christine Lavery(Amersham Hospital), Michael Rudnicki(Innsbruck Medical University), Lut Boks(Amersham Hospital)
Orphanet Journal of Rare Diseases
March 27, 2015
Cited by 345


Related Papers